(184i) Comparison Among Lnp, PNP and Exosomes for Gene Delivery to Treat Triple-Negative Breast Cancer

The gene therapy for cancer treatment needs efficient, stable and safe delivery vehicles. The goal of this study was to compare three gene delivery vehicles, i.e. cationic lipid nanoparticles (LNPs) using traditional DOTAP and DOPE, RALA peptide nanoparticles (PNPs), and exosome nanoparticles (Exo). Specifically, we synthesized or produced these three vehicles and characterized them with NanoSight, Zeta and TEM. The gene packing rate of our mitochondria-targeting mLumiOpto genes was compared using RT-PCR. The cancer specificity was tested by surface tagging our monoclonal antibody that was developed to target the surface receptor overexpressed in triple-negative breast cancers (TNBCs). Then, we evaluated the transfection/transduction efficiency and functional gene expression using multiple TNBC cell lines. Finally, the in vivo cancer targeting and gene delivery were evaluated and compared. Taken together, this study provided a full comparison of three nanoparticles for cancer targeting and gene therapy.